506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment [clinicaltrials:NCT00004239]
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment [clinicaltrials:NCT00004239]
Bio2RDF identifier
NCT00004239
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00004239
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Drugs used i ...... d kidney or liver impairment.
brief title [clinicaltrials_vocabulary:brief-title]
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
collaborator [clinicaltrials_vocabulary:collaborator]
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES: I. Determin ...... ll be accrued for this study.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2000-01-28T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
is section 801 [clinicaltrials_vocabulary:is-section-801]
keyword [clinicaltrials_vocabulary:keyword]
Waldenstrom macroglobulinemia
anaplastic large cell lymphoma
chronic myelomonocytic leukemia
essential thrombocythemia
extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
nodal marginal zone B-cell lymphoma
polycythemia vera
previously treated myelodysplastic syndromes
primary myelofibrosis
primary systemic amyloidosis
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2011-05-23T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00004239
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
A Phase I Study of Compound 50 ...... nd Renal or Hepatic Impairment
org study id [clinicaltrials_vocabulary:org-study-id]
CDR0000067483
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
U10CA031946
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1999-12-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2011-05-01T00:00:00Z
why stopped [clinicaltrials_vocabulary:why-stopped]
poor accrual
identifier
clinicaltrials:NCT00004239
title
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
@en
type
label
506U78 in Treating Patients Wi ...... t [clinicaltrials:NCT00004239]
@en